Druker BJ - Search Results

1

Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.

Frater JL, Tallman MS, Variakojis D, Druker BJ, Resta D, Riley MB, Hrisinko MA, Peterson LC. Frater JL, et al. Among authors: druker bj. Am J Clin Pathol. 2003 Jun;119(6):833-41. doi: 10.1309/A4RG-P4LF-12GG-H8MW. Am J Clin Pathol. 2003. PMID: 12817431 Clinical Trial.

2

Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience.

Braziel RM, Launder TM, Druker BJ, Olson SB, Magenis RE, Mauro MJ, Sawyers CL, Paquette RL, O'Dwyer ME. Braziel RM, et al. Among authors: druker bj. Blood. 2002 Jul 15;100(2):435-41. doi: 10.1182/blood.v100.2.435. Blood. 2002. PMID: 12091333 Free article.

3

Imatinib alone and in combination for chronic myeloid leukemia.

Druker BJ. Druker BJ. Semin Hematol. 2003 Jan;40(1):50-8. doi: 10.1053/shem.2003.50000. Semin Hematol. 2003. PMID: 12563611 Review.

4

Practical management of patients with chronic myeloid leukemia receiving imatinib.

Deininger MW, O'Brien SG, Ford JM, Druker BJ. Deininger MW, et al. Among authors: druker bj. J Clin Oncol. 2003 Apr 15;21(8):1637-47. doi: 10.1200/JCO.2003.11.143. Epub 2003 Mar 13. J Clin Oncol. 2003. PMID: 12668652 Review.

5

Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study.

Hahn EA, Glendenning GA, Sorensen MV, Hudgens SA, Druker BJ, Guilhot F, Larson RA, O'Brien SG, Dobrez DG, Hensley ML, Cella D; IRIS Investigators. Hahn EA, et al. Among authors: druker bj. J Clin Oncol. 2003 Jun 1;21(11):2138-46. doi: 10.1200/JCO.2003.12.154. J Clin Oncol. 2003. PMID: 12775739 Clinical Trial.

6

Chronic myeloid leukemia in the imatinib era.

Druker BJ. Druker BJ. Semin Hematol. 2003 Apr;40(2 Suppl 2):1-3. doi: 10.1053/shem.2003.50033. Semin Hematol. 2003. PMID: 12783367 Review.

7

Imatinib mesylate in the treatment of chronic myeloid leukaemia.

Druker BJ. Druker BJ. Expert Opin Pharmacother. 2003 Jun;4(6):963-71. doi: 10.1517/14656566.4.6.963. Expert Opin Pharmacother. 2003. PMID: 12783592 Review.

8

Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.

Peng B, Hayes M, Resta D, Racine-Poon A, Druker BJ, Talpaz M, Sawyers CL, Rosamilia M, Ford J, Lloyd P, Capdeville R. Peng B, et al. Among authors: druker bj. J Clin Oncol. 2004 Mar 1;22(5):935-42. doi: 10.1200/JCO.2004.03.050. J Clin Oncol. 2004. PMID: 14990650 Clinical Trial.

9

The development of imatinib as a therapeutic agent for chronic myeloid leukemia.

Deininger M, Buchdunger E, Druker BJ. Deininger M, et al. Among authors: druker bj. Blood. 2005 Apr 1;105(7):2640-53. doi: 10.1182/blood-2004-08-3097. Epub 2004 Dec 23. Blood. 2005. PMID: 15618470 Free article. Review.

10

Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib.

O'Hare T, Walters DK, Stoffregen EP, Sherbenou DW, Heinrich MC, Deininger MW, Druker BJ. O'Hare T, et al. Among authors: druker bj. Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6987-93. doi: 10.1158/1078-0432.CCR-05-0622. Clin Cancer Res. 2005. PMID: 16203792

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

442 results

Search Page

Filters